Pseudotyped recombinant lyssaviruses for gene therapy
AssigneeBeam Therapeutics Inc.
InventorsFei Ran, ChieYu Lin
Life of this patent
Estimating the term…
Abstract
Provided herein are pseudotyped recombinant lyssavirus particles and methods for their use in delivering a transgene into a target cell. Also provided are packaging systems and methods of using the packaging systems to produce pseudotyped recombinant lyssavirus particles.
Claims38
A pseudotyped recombinant lyssavirus particle, comprising a heterologous envelope protein and a recombinant lyssavirus genome, wherein
- the recombinant lyssavirus genome does not encode an endogenous envelope protein or fragment thereof and comprises a nucleic acid encoding a therapeutic transgene.
3-9. (canceled)
(canceled)
13-15. (canceled)
17-18. (canceled)
20-23. (canceled)
(canceled)
27-28. (canceled)
30-32. (canceled)
34-43. (canceled)
45-49. (canceled)
51-53. (canceled)
A pseudotyped recombinant lyssavirus particle, comprising a heterologous envelope protein and a recombinant lyssavirus genome, wherein
- the heterologous envelope protein is a envelope protein of a virus in the Togaviridae family;
- the recombinant lyssavirus genome does not encode an endogenous envelope protein or fragment thereof and comprises a nucleic acid encoding a therapeutic transgene.
56-57. (canceled)
A pseudotyped recombinant lyssavirus particle, comprising a heterologous envelope protein and a recombinant lyssavirus genome, wherein
- the heterologous envelope protein is a envelope protein of a virus in the Filoviridae family;
- the recombinant lyssavirus genome does not encode an endogenous envelope protein or fragment thereof and comprises a nucleic acid encoding a therapeutic transgene.
60-80. (canceled)
85-87. (canceled)
91-102. (canceled)
Dependencies are inferred from the claim text.